Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128290) titled 'PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Federation Francophone de Cancerologie Digestive
Condition:
Intrahepatic Cholangiocarcinoma (Icc)
Intervention:
Drug: CISGEM + Rilvegostomig
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 30, 2025
Target Sample Size: 49
Countries of Recruitment:
France
To know more, visit https://clinica...